Cancerify Logo
Log inSign up
Back to clinical trials
RecruitingInterventionalPhase 2

Rectus Sheath Block With Liposomal Bupivacaine Versus Thoracic Epidural Analgesia for Pain Control Following Pancreatoduodenectomy: A Prospective, Randomized, Non-Inferiority Trial

NCT ID: NCT06411795Sponsor: Masonic Cancer Center, University of MinnesotaLast updated: 2026-02-03

Summary

This phase II trial compares the effect of rectus sheath block with liposomal bupivacaine to thoracic epidural analgesia (TEA) on pain control in patients following surgical removal of all or part of the pancreas and duodenectomy (pancreatoduodenectomy). Administering long acting local anesthetics, such as liposomal bupivacaine, in between the muscle layers of the abdomen (rectus sheath block) may help with pain relief during and after surgery. TEA uses a needle to insert a flexible plastic catheter into the thoracic spine to administer anesthetic and pain medication, such as bupivacaine and hydromorphone, to treat pain in the thoracic and upper abdominal areas during and after surgery. Epidurals have been successfully used to treat pain after surgery, however, it does have a risk of low blood pressure which may limit the use in the thoracic approach. Rectus sheath blocks with liposomal bupivacaine may be as effective as TEA in reducing pain in patients following a pancreatoduodenectomy.

Detailed description

PRIMARY OBJECTIVE: I. To determine if rectus sheath blocks with liposomal bupivacaine provide non-inferior analgesia compared with thoracic epidural analgesia (TEA) for patients undergoing pancreatoduodenectomy. OUTLINE: Patients are randomized to 1 of 2 groups. GROUP EPIDURAL (E): Prior to pancreatoduodenectomy, patients undergo thoracic epidural placement and receive bupivacaine and hydromorphone continuous infusion via epidural for up to 72 hours postoperatively. Patients also receive iopamidol via epidural and undergo x-ray imaging on study. GROUP RECTUS SHEATH (RS): Prior to pancreatoduodenectomy, patients undergo ultrasound and receive bupivacaine and liposomal bupivacaine injection into the rectus sheath.

Arms & interventions

  • DrugBupivacaine

    Given via epidural and injection

  • DrugHydromorphone

    Given via epidural

  • DrugIopamidol

    Given via epidural

  • DrugLiposomal Bupivacaine

    Given injection

  • OtherMedical Chart Review

    Ancillary studies

  • OtherQuestionnaire Administration

    Ancillary studies

  • DrugThoracic Epidural Analgesia

    Undergo thoracic epidural placement

  • ProcedureUltrasound Imaging

    Undergo ultrasound

  • ProcedureX-Ray Imaging

    Undergo x-ray

Outcome measures

Primary

  • Milligram morphine equivalents (MME)

    Opioid consumption will be evaluated as a non-inferiority hypothesis using a two-sample t-test to compare the groups, with the conclusion of statistical significance being drawn from the corresponding confidence interval for the differences in mean MMEs between groups.

    Time frame: Up to 96 hours after open pancreatoduodenectomy

Secondary

  • Pain scores

    Time frame: At 24, 48, 72 and 96 hours

  • Hospital length of stay

    Time frame: Up to 7 days after surgery

  • Opioid consumption

    Time frame: 96 hours

  • Time to return of bowel function

    Time frame: Up to 7 days after surgery

  • Incidence of nausea, vomiting, hypotension and pruritis

    Time frame: At 24 hours, 48 hours, 72 hours and 96 hours

Eligibility criteria

Sex: AllAge: 18 Years and olderHealthy volunteers: No
Inclusion Criteria: * Adult patients, age 18 and older, undergoing open pancreaticoduodenectomy at the University of Minnesota will be included in the study Exclusion Criteria: * Patients with contraindication to block placement (coagulopathy, local anesthetic allergy, infection) * Patients with chronic opioid use (at least 30 milligram morphine equivalents \[MME\] for 3 or more weeks leading up to surgery) * Patients unable to understand the quality of recovery survey intellectual barriers. This will be determined by the primary investigator/attending anesthesiologist's discretion * Patient refusal and those who have opted out of research * Pregnant patients - will be assessed through review of the medical record

Study locations (1)

University of Minnesota/Masonic Cancer Center

Minneapolis, Minnesota, 55455

Recruiting
James Flaherty · Contact
James Flaherty · Principal Investigator